Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesEikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
6.28 USD -0.39 ( 5.85%)
Last update at 2026-11-12T15:38:00Z
VOLUME
106995
Market Cap
514.03M

Momentum Score

…

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.07
Low
6.72
High
52 Week Price Range
7.90
Low
17.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eikon Therapeutics develops a drug-discovery platform that combines high-resolution single-molecule imaging and machine learning to observe protein dynamics and identify therapeutic candidates. Long-term growth may be driven by validation of its platform through successful preclinical-to-clinical progress, partnerships with larger biopharma, and an expanding discovery pipeline that could support recurring collaborations and licensing revenue.

Principal risks include an early-stage, unproven platform and pipeline with no commercial products, high cash burn and potential dilution, regulatory and execution uncertainty, and strong competition in computational and experimental drug discovery.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.67
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-125.02%
Net Debt
-
ROCE
-62.80%
Diluted EPS TTM
-6.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax -324.25M -243.81M -242.00M
Net income -324.25M -243.81M -242.00M
Selling general administrative 88.63M 55.81M 58.48M
Reconciled depreciation 24.18M 25.39M 17.75M
Operating income -338.94M -260.34M -265.74M
Interest expense 0.84M 0.03M 0.04M
Interest income 15.57M 16.56M 23.74M
Net interest income 14.73M 16.53M 23.70M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 338.94M 260.34M 265.74M
Total other income expense net -0.03M -0.00M 0.04M
Net income from continuing ops -324.25M -243.81M -242.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 594.73M 491.24M 525.71M
Other current assets 12.54M 7.38M 6.01M
Total liab 1473.77M 1063.17M 867.08M
Total stockholder equity -879.03M -571.93M -341.37M
Other current liab 0.04M 0.30M 0.59M
Capital stock 0.00M 0.00M 0.00M
Retained earnings -920.51M -604.94M -361.13M
Cash 104.90M 129.18M 112.78M
Total current liabilities 55.01M 56.45M 31.44M
Total current assets 348.92M 227.89M 436.43M
Short term investments 231.07M 90.93M 317.63M
Accounts payable 0.68M 17.58M 2.19M
Non currrent assets other 8.35M 4.22M 2.40M
Non current assets total 245.82M 263.35M 89.28M
Capital lease obligations 257.32M 202.46M 31.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Investments -134.60M 236.15M 165.46M
Total cash from financing activities 352.05M 0.24M 105.81M
Net income -324.25M -243.81M -242.00M
Change in cash -17.81M 16.80M 51.91M
Begin period cash flow 130.88M 114.08M 62.17M
End period cash flow 113.07M 130.88M 114.08M
Total cash from operating activities -188.52M -134.80M -190.85M
Issuance of capital stock 352.05M 0.24M 105.81M
Depreciation 24.18M 25.39M 17.75M
Capital expenditures 46.74M 84.80M 28.51M
Change in working capital 77.83M 80.65M 9.98M
Stock based compensation 18.04M 12.43M 9.54M
Other non cash items -5.54M -9.46M 13.89M
Free cash flow -235.26M -219.60M -219.36M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
EIKN
Eikon Therapeutics, Inc. Common Stock		 -0.39
5.85%		 6.28 - - - 1.09
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

230 Harriet Tubman Way, Millbrae, CA, United States, 94030

341 777 0566

https://eikontx.com

384

Name Title Year Born
Dr. Roger M. Perlmutter M.D., Ph.D. Chairman, President & CEO 1952
Mr. Michael A. Klobuchar Chief Operating Officer 1976
Dr. Roy D. Baynes FACP, M.D., Ph.D. Executive VP & Chief Medical Officer 1955
Dr. Robert Tjian Ph.D. Co-Founder & Member of Scientific Advisory Board 1949
Dr. Eric Betzig Ph.D. Co-Founder & Member of Scientific Advisory Board NA
Dr. Alfred Lloyd Bowie Jr., Ph.D. Treasurer & CFO 1982
Mr. Russ Berman Chief Technology Officer NA
Mr. Benjamin Bruno Thorner Secretary, General Counsel & Chief Business Officer 1971
Ms. Barbara Howes M.B.A. Chief People Officer 1965
Dr. Ching-Pin Chang M.D., Ph.D. Executive VP & Chief Scientific Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…